XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues:        
Total revenue $ 167.3 $ 145.2 $ 529.8 $ 402.4
Costs and expenses:        
Research and development expense 18.8 17.6 61.4 54.7
Selling, general, and administrative expense 180.2 124.1 460.5 364.4
Change in the fair value of contingent consideration 0.4 (1.1) 1.7 (4.5)
Goodwill and long-lived asset impairment charges 0.0 0.0 1.8 98.4
Total costs and expenses 247.2 184.8 677.2 644.0
Operating loss (79.9) (39.6) (147.4) (241.6)
Other income (expense):        
Interest income 0.2 0.4 0.6 1.7
Interest expense (1.1) (2.9) (6.1) (8.3)
Other 120.6 (1.6) 139.3 14.9
Total other income (expense), net 119.7 (4.1) 133.8 8.3
Income (loss) before income tax 39.8 (43.7) (13.6) (233.3)
Income tax expense (benefit) 15.2 (28.5) 6.0 (47.4)
Net income (loss) 24.6 (15.2) (19.6) (185.9)
Net loss attributable to non-controlling interest 0.0 0.0 0.0 (0.1)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ 24.6 $ (15.2) $ (19.6) $ (185.8)
Net income (loss) per share:        
Basic (in dollars per share) $ 0.31 $ (0.20) $ (0.25) $ (2.49)
Diluted (in dollars per share) $ 0.30 $ (0.20) $ (0.25) $ (2.49)
Weighted average shares outstanding:        
Basic (shares) 78.8 74.7 77.3 74.6
Diluted (shares) 81.5 74.7 77.3 74.6
Molecular diagnostic testing        
Revenues:        
Total revenue $ 167.3 $ 135.7 $ 505.6 $ 369.5
Costs and expenses:        
Cost of revenue 47.8 39.9 139.9 115.2
Pharmaceutical and clinical services        
Revenues:        
Total revenue 0.0 9.5 24.2 32.9
Costs and expenses:        
Cost of revenue $ 0.0 $ 4.3 $ 11.9 $ 15.8